Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis

Next Previous
X
Search
Trial Profile

An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared With Best Available Therapy for Patients With Advanced Systemic Mastocytosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Leukaemia; Systemic mastocytosis
  • Focus Therapeutic Use
  • Sponsors Blueprint Medicines

    • Most Recent Events

    • 01 Oct 2022 Results (n=202) assessing comparison of OS in NCT04695431 and in patients with SM-AHN treated with avapritinib in EXPLORER and PATHFINDER versus patients treated with BAT in standard clinical practice published in the Clinical Lymphoma, Myeloma & Leukemia
    • 02 Aug 2022 According to a Blueprint Medicines media release, results from the trial were presented at the European Hematology Association (EHA) 2022 Congress.
    • 01 Aug 2022 Results of a pooled analysis comparing clinical outcomes from NCT04695431 and EXPLORER, PATHFINDER published in the Leukemia

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top